The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
 
Elisa A. Rozeman
Travel, Accommodations, Expenses - MSD; NanoString Technologies
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - Amgen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - Amgen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Novartis; Roche
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Myles Smith
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Loes M. Pronk
No Relationships to Disclose
 
Maria Gonzales
No Relationships to Disclose
 
Christoph Hoeller
No Relationships to Disclose
 
Johan Hansson
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis
 
James M. G. Larkin
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech
 
Christian U. Blank
Stock and Other Ownership Interests - Verastem
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche